View Older Stories View More Recent Stories
-
Hims & Hers Health (HIMS) said to stop offering weight loss pill
-
FDA moves to restrict copycat GLP-1 weight loss drugs
-
Hims & Hers stock falls after FDA warns against illegal copycat drugs
-
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
-
Novo shares rebound as FDA vows crackdown on weight-loss drug copies
-
Truist: 'Defending Lilly: LLY strong position helps guard their share in a crowded GLP-1 landscape'
-
Novo Nordisk threatens legal action over Hims & Hers semaglutide pill
-
Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
-
Wolfe Research on Eli Lilly (LLY): 'we question the legality of HIMS' ability to market an oral semaglutide'
-
Wells Fargo on Eli Lilly (LLY): 'Compounders Strike Again, but We See Little Risk to Near-Term Growth'
-
BMO Capital: 'Novo Mgmt Meetings Highlight Deep Strategic Challenges'
-
Novo Nordisk (NVO) PT Lowered to $45 at BMO Capital Following 'Soft' Guide
-
Hims stock surges as Wegovy pill copy offered at $49, Novo shares fall
-
Hims & Hers adds compounded semaglutide pills starting at $49 monthly
-
Hims & Hers Health (HIMS) launches a copy of Wegovy pill at $49/month
-
BMO Capital on Novo Nordisk: 'Expect NVO shares to remain pressured today'
-
Novo Nordisk shares plunge amid lower 2026 sales outlook
-
Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
-
Eli Lilly & Co. (LLY) sees volatility amid Novo's warning
-
Novo Nordisk reports 2025 sales growth, cuts 2026 outlook
-
Novo Nordisk (NVO) Halted, News Pending
-
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO)
-
Novo Nordisk's CagriSema shows superior diabetes control in phase 3 trial
-
Walmart raises pharmacy technician wages as it expands healthcare services
-
Citi initiates coverage of European pharma stocks; AstraZeneca 'best in class'
-
Novo Nordisk (NVO) PT Raised to $57 at BMO Capital
-
This stock is Kepler's top pick in the European pharma sector
-
Novo Nordisk (NVO) call put ratio 2.3 calls to 1 put with a focus as share price up 8.5%
-
Novo Nordisk's oral Wegovy reaches 3,071 prescriptions in first four days
-
Novo Nordisk stock target raised at UBS ahead of Wegovy Pill launch
-
BMO Capital: 'Novo Nordisk (NVO) Aims to Regain Obesity Leadership as Orals Expand Market'
-
Novo Nordisk CEO warns of international competition headwinds, cites Lilly
-
Novo Nordisk (NVO) EVP for product and portfolio strategy: market for oral weight-loss drugs versus injectables bigger than originally thought
-
Amazon Pharmacy adds Novo Nordisk's Wegovy pill with insurance coverage
-
Novo Nordisk (NVO) call put ratio 1.9 calls to 1 put into the annual J.P. Morgan Healthcare Conference
-
Novo Nordisk's (NVO) U.S. public affairs head departs - Reuters
-
Novo Nordisk launches oral Wegovy pill for weight loss across US
-
China's top court upholds Novo Nordisk semaglutide patent validity
-
Novo Nordisk reportedly cut Wegovy prices in China by half
-
Popular stocks with increasing option volume: NVO MU FITB MSTR ORCL RKLB WMT INTC AVGO HOOD
-
BMO Capital on Novo Nordisk (NVO): 'FDA Approval Brings Much-Needed Cheer'
-
ZIM, Novo Nordisk rise in premarket, space stocks fall
-
Novo Nordisk shares jump after FDA approves first GLP-1 weight-loss pill
-
Novo Nordisk (NVO) call put ratio 3.6 calls to 1 put into FDA approval of Wegovy in weight loss
-
Novo Nordisk's Wegovy pill wins FDA approval as first oral GLP-1 for weight loss
-
Here's the list of top biotech stocks to own for 2026
-
Trump to announce prescription drug price agreements
-
White House: Trump on Friday to announce more 'deals that will lower prices of drugs and pharmaceuticals'
-
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
-
BofA Comments on GLP-1s and Potential Pressure Ahead
